Here’s what you should know:
1. Although Bekinda did meet its primary endpoint of improved stool consistency, it did not meet its secondary endpoints of improved abdominal pain or improved overall response in patients.
2. Shares of RedHill closed at $10.81 Oct. 2. They fell to $9.03 Oct. 3, before closing at $9.39 later in the day.
3. RedHill’s Chief Executive Dror Ben-Asher told Reuters, the study wasn’t designed to show significance in the secondary endpoints. He said, “The results are actually good according to the small sample size.”
4. RedHill anticipates beginning a late-stage trial on Bekinda by late 2018.
More articles on gastroenterology:
GI leader to know: Dr. Steven Desautels of Granite Peaks Gastroenterology
Stock market week-in-review for 5 large GI companies — Sept. 25-29
Drug designations, new devices & more — 15 GI company key notes for September
